This is a routine Section 16(a) filing with no trading signal. Monitor for any subsequent Form 4 filings that would indicate insider buying or selling, which would be more informative for FLSC's prospects.
Price Chart
Executive Summary
Fran Adams, the new Chief Financial Officer of Frazier Life Sciences Acquisition Corp. II (FLSC), filed a Form 3 initial statement of beneficial ownership, reporting 14,063 Class A ordinary shares held indirectly (via a derivative interest in Class B shares that convert to Class A upon a business combination). This is a routine insider filing required upon appointment as an officer, with no trading activity or material change in ownership.
Key Facts
- Fran Adams appointed as Chief Financial Officer of Frazier Life Sciences Acquisition Corp. II.
- Form 3 filed on 2026-10-13, reporting 14,063 Class A ordinary shares (derived from Class B shares convertible 1:1 upon business combination).
- No open-market purchases or sales; filing is a routine initial beneficial ownership statement.
- Class B shares have no expiration date and convert automatically upon consummation of the issuer's initial business combination.
Financial Impact
No financial impact; the filing is a regulatory formality with no transaction or change in capital structure.
Risk Factors
- No material risks identified from this filing.
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-420801 |
| Document: 0001193125-26-420801-index-headers.html | 0001193125-26-420801 |
| Document: 0001193125-26-420801-index.html | 0001193125-26-420801 |
| Document: 0001193125-26-420801.txt | 0001193125-26-420801 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $10.30 | awaiting T+5 | — | $10.24 (−0.63%) |
Oct 22, 2026 4d ago | SC 13G | $10.30 | awaiting T+5 | — | $10.24 (−0.63%) |
Oct 21, 2026 5d ago | SC 13D | $10.27 | awaiting T+5 | — | $10.24 (−0.34%) |
Oct 21, 2026 5d ago | SC 13G | $10.27 | awaiting T+5 | — | $10.24 (−0.34%) |
Oct 21, 2026 5d ago | SC 13G | $10.27 | awaiting T+5 | — | $10.24 (−0.34%) |
Oct 16, 2026 11d ago | SC 13G | $10.35 $10.30 | ▼ −0.48% | ▼ −0.05% | $10.24 (−1.11%) |
Oct 15, 2026 11d ago | Insider Buy | $10.35 $10.30 | ▼ −0.48% | ▼ −0.05% | $10.24 (−1.11%) |
Oct 15, 2026 11d ago | 8-K | $10.35 $10.30 | ▼ −0.48% | ▼ −0.05% | $10.24 (−1.11%) |
Oct 14, 2026 12d ago | 424B4 | $10.49 $10.27 | ▼ −2.10% | ▼ −1.08% | $10.24 (−2.43%) |
Oct 14, 2026 13d ago | EFFECT | $10.29 $10.30 | ▲ +0.10% | ▼ −0.36% | $10.24 (−0.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers